• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

MC Services AG

MC Services AG, based in Munich and Duesseldorf, is an international Public Relations and Investor Relations firm specializing in Investor Relations and Corporate Communications. The Company's long-standing clients include leading, international public and private companies as well as venture capitalists and investment firms. Established for many years as a link between the health care industry and the financial markets, MC Services provides comprehensive services in the fields of IR, PR, financial reporting as well as capital and corporate transactions. We leverage our extensive network in the international financial community and in the industry in a targeted way for the benefit of our clients in order to best prepare for financial transactions by means of qualified investor relations and media relations, for example, or to visibly position our clients and their successes in the international finance, economic and trade media. *

 

	Start	1999-01-01 established
	Industry	public relations / investor relations / marcom (services)
	Industry 2	LIFE SCIENCES
	Person	Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)
	Person 2	Steinel, Susanne (MC Services 201101 Executive Board Member)
	Region	München (Munich)
	Country	Germany
	Street	26 Bavariaring
	City	80336 München
	Tel	+49-89-210228-0
		Address record changed: 2018-07-24
Basic data	Employees	n. a.
		* Document for �About Section�: MC Services AG. (12/11/13). "Press Release: MC Services Strengthens Life Sciences Expertise with the Addition of Dr. Solveigh Mähler". Düsseldorf.
		Record changed: 2019-06-06

Advertisement

More documents for MC Services AG

• [1] InflaRx N.V.. (6/5/19). "Press Release: InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa". Jena....
• [2] Cevec Pharmaceuticals GmbH. (4/16/19). "Press Release: Cevec Closes Major Financing Round to Further Expand and Commercialize Its Viral Vector Manufacturing Platform". Cologne....
• [3] InflaRx N.V.. (2/6/19). "Press Release: InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [4] Atriva Therapeutics GmbH. (1/3/19). "Press Release: Atriva Therapeutics Announces First Closing of Series A Financing Round". Tübingen....
• [5] InflaRx N.V.. (11/8/18). "Press Release: InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [6] AiCuris Anti-infective Cures GmbH. (9/3/18). "Press Release: AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B". Wuppertal....
• [7] Secarna Pharmaceuticals GmbH & Co. KG. (6/4/18). "Press Release: Secarna Pharmaceuticals Introduces LNAplus, Its Proprietary, Customized, Third Generation Antisense Oligonucleotide (ASO) Drug Discovery and Development Platform". Martinsried....
• [8] MAB Discovery GmbH. (4/5/18). "Press Release: EUROSTARS Grants Project Funding for SPARKLE Consortium". Neuried....
• [9] InflaRx N.V.. (3/8/18). "Press Release: InflaRx Announces First Patient Enrolled in Phase IIb Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa". Jena....
• [10] MC Services AG. (10/18/17). "Press Release: MC Services Supports BIO-Europe Berlin as Media Partner". Munich & Düsseldorf....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.